# BD<sup>™</sup> Cytometric Bead Array (CBA)



## **Technical Data Sheet** Human Eotaxin Flex Set

#### Product Information

| Material Number:      |
|-----------------------|
| Size:                 |
| <b>Bead Position:</b> |
| Assay Range:          |
| Reactivity:           |

558329 100 Tests C7 10-2,500 pg/mL QC Testing: Human

Component Description: Component Mat. No: Component Storage Buffer:

Component Description: Component Mat. No: Component Storage Buffer:

Component Description: Component Mat. No: Component Storage Buffer: Human Eotaxin Standard 51-9004224 Lyophilized in an aqueous buffered solution containing BSA and ProClin<sup>™</sup> 150.

Human Eotaxin PE Detection Reagent 51-9004227 Aqueous buffered solution containing BSA and ≤0.09% sodium azide.

Human Eotaxin Capture Bead C7 51-9005344 Aqueous buffered solution containing fetal bovine serum and  $\leq 0.09\%$  sodium azide.




Figure 1. Example BD CBA Human Eotaxin Flex Set standard curve. Data acquired on a BD FACSArray bioanalyzer and analyzer using FCAP Array Software.

### Description

The BDTM CBA Human Eotaxin Flex Set is a bead-based immunoassay capable of measuring human Eotaxin, also known as CCL11, in serum, plasma, and cell culture supernatant samples. Human reactivity was determined by testing samples with the BD CBA Human Eotaxin Flex Set. The biology and function of Eotaxin has been extensively reviewed in the literature. For more information on bead-based immunoassays, refer to the product insert for the BD CBA Human Soluble Protein Master Buffer Kit (Cat. No. 558264 or 558265).

#### Preparation and Storage

This BDTM CBA Flex Set contains one vial each of Capture Bead and PE Detection Reagent and two vials of Standard. The Capture Bead and PE Detection Reagent components of this flex set have been formulated to a 50x concentration to ensure product performance when multiplexed. The Standard component is lyophilized and should be transferred to a 15 mL polypropylene tube for reconstitution. When reconstituted in 4.0 mL Assay Diluent, the standard has a protein concentration of 2,500 pg/mL. Discard unused reconstituted standard, do not store or reuse. Store lyophilized standard and other components at 4°C. Protect Capture Beads and the PE Detection Reagent from prolonged exposure to light.

#### Application Notes

Recommended Assay Procedure: The BD CBA Human Eotaxin Flex Set must be used in conjunction with a BD CBA Human Soluble Protein Master Buffer Kit (Cat. No. 558264, 100 tests, or 558265, 500 tests), a flow cytometer, and FCAP Array™ Software. Detailed instructions on the use of this product can be found in the manual for the BD CBA Human Soluble Protein Master Buffer Kit. When following the directions in the Master Buffer Kit, the top standardpoint for the BD CBA Human Eotaxin Flex Set will be 2,500 pg/mL. An example standard curve is shown in Figure 1.

The BD CBA Human Eotaxin Flex Set should not be used in the same assay well any non-BD CBA Human Soluble Protein Flex Set reagents

#### **BD** Biosciences

| bdbiosciences.com  |                       |                             |                         |                       |                                  |  |  |  |
|--------------------|-----------------------|-----------------------------|-------------------------|-----------------------|----------------------------------|--|--|--|
| United States      | <b>Canada</b>         | Europe                      | <b>Japan</b>            | Asia Pacific          | Latin America/Caribbear          |  |  |  |
| 877.232.8995       | 800.268.5430          | 32.2.400.98.95              | 0120.8555.90            | 65.6861.0633          | 55.11.5185.9995                  |  |  |  |
| For country cor    | ntact informatio      | on, visit <b>bdbiosci</b> e | ences.com/conta         | ct                    |                                  |  |  |  |
| of any patents. BL | D Biosciences will no | ot be held responsik        | ble for patent infrin   | gement or other vio   | e the above product in violation |  |  |  |
| use of our product | ts. Purchase does n   | ot include or carry a       | any right to resell or  | r transfer this produ | vlations that may occur with the |  |  |  |
| product or as a co | mponent of anoth-     | er product. Any use         | of this product oth     | er than the permitte  | ct either as a stand-alone       |  |  |  |
| written authoriza  | tion of Becton, Dica  | kinson and Compan           | by is stictly prohibite | d.                    | ed use without the express       |  |  |  |
| For Research Use   | Only. Not for use in  | diagnostic or thera         | apeutic procedures.     | Not for resale.       | an and Company. © 2014 BD        |  |  |  |

(such as BD CBA Mouse Soluble Protein or Cell Signaling Flex Sets). For an updated assay compatibility chart for the BD CBA Human Soluble Protein Flex Sets, please refer to the BD CBA Flex Set System homepage at http://www.bdbiosciences.com/cbasetup.

#### Performance

Limit of Detection: The theoretical limit of detection is 0.8 pg/mL and was determined by evaluating the estimated result of the average MFI of the negative control (0 pg/mL, n=30) + 2 standard deviations.

| Specificity   |          | Inter-Assay Reproducibility |                       |     | Intra-Assay Reproducibility |                       |     |  |
|---------------|----------|-----------------------------|-----------------------|-----|-----------------------------|-----------------------|-----|--|
|               |          | Mean<br>(pg/ml)             | Standard<br>Deviation | %CV | Mean<br>(pg/ml)             | Standard<br>Deviation | %CV |  |
| Sample 1      |          | 33.1                        | 3.8                   | 11% | 31.5                        | 1.5                   | 5%  |  |
| Human Eotaxin | Sample 2 | 138.9                       | 9.7                   | 7%  | 124.5                       | 7.7                   | 6%  |  |
|               | Sample 3 | 563.5                       | 31.3                  | 6%  | 534.7                       | 15.9                  | 3%  |  |

Reproducibility: The inter-assay and intra-assay reproducibility were determined for the BD CBA Human Eotaxin Flex Set by evaluating ten replicates of three different sample levels (inter-assay) and two replicates of three different sample levels from four separate experiments (intra-assay) respectively

|               | Cell Culture<br>Supernatant |          | Ser                      | um       | Plasma                   |          |
|---------------|-----------------------------|----------|--------------------------|----------|--------------------------|----------|
| Specificity   | Average<br>%<br>Recovery    | Range    | Average<br>%<br>Recovery | Range    | Average<br>%<br>Recovery | Range    |
| Human Eotaxin | 81%                         | 80 - 84% | 71%                      | 51 - 84% | 76%                      | 74 - 77% |

Recovery: Cell culture supernatant, serum, or EDTA-treated plasma were spiked with three different levels of protein. The spiked samples were assayed and the results were compared with expected values. Serum and plasma samples were diluted 1:4 before the protein was spiked into each. Serum is a pool of 800 - 1000 donors and the plasma was pooled from at least 20 donors.

| Comple Dilution | Cell Culture<br>Supernatant |                  | Ser                 | um               | Plasma              |                  |
|-----------------|-----------------------------|------------------|---------------------|------------------|---------------------|------------------|
| Sample Dilution | Detected<br>(pg/ml)         | % of<br>Expected | Detected<br>(pg/ml) | % of<br>Expected | Detected<br>(pg/ml) | % of<br>Expected |
| Spiked sample   | 448.9                       | 100%             | 514.4               | 100%             | 500.8               | 100%             |
| 1:2             | 219.4                       | 98%              | 247.8               | 96%              | 222.8               | 89%              |
| 1:4             | 104.0                       | 93%              | 118.8               | 92%              | 112.7               | 90%              |

Linearity: Cell culture supernatant, 1:4 diluted serum, or 1:4 diluted EDTA-treated plasma were spiked with protein and serially diluted. The diluted samples were assayed and the results were compared with the original spiked sample

#### **Product Notices**

- 1. ProClin is a trademark of Rohm and Haas Company.
- 2. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before 3. discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Warning: CBA lyophilized standard contains 0.02% (w/w) of a CMIT/MIT mixture (3:1), which is a mixture of: 4. 5-chloro-2-methyl-4-isothiazolin-3-one [EC No 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC No 220-239-6] (3:1). Hazard statement: May cause an allergic skin reaction.

Precautionary statements: Wear protective gloves/eye protection. Wear protective clothing. Avoid breathing mist/vapours/spray. If skin irritation or rash occurs: Get medical advice/attention. IF ON SKIN: Wash with plenty of water. Dispose of contents/container in accordance with local/regional/national/international regulations.

| BD Biosciences<br>bdbiosciences.com     |   |  |   |  |  |  |  |  |
|---|---|--|---|--|--|--|--|--|
| United States<br>877.232.8995           | Canada<br>800.268.5430                      | Europe<br>32.2.400.98.95                             |   | Asia Pacific<br>65.6861.0633                 | Latin America/Caribbear<br>55.11.5185.9995   |  |  |  |
|   |   | on, visit <b>bdbiosci</b> e<br>d herein is not to be |   |  | e the above product in violation   |  |  |  |
| of any patents. BL<br>use of our produc | D Biosciences will n<br>ts. Purchase does n | ot be held responsil<br>ot include or carry a        | ole for patent infrin<br>any right to resell or | gement or other vio<br>r transfer this produ | ations that may occur with the<br>ct either as a stand-alone<br>ad use without the express |  |  |  |

written authorization of Becton, Dickinson and Company is stictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale. Unless otherwise noted, BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2014 BD